AbbVie, CervoMed, Thermo Fisher Scientific, Danaher, Vertex Pharmaceuticals, Cencora, and Cognizant Technology Solutions are the seven Biotech stocks to watch today, according to MarketBeat’s stock ...
AbbVie, Danaher, and Thermo Fisher Scientific are the three Biotech stocks to watch today, according to MarketBeat’s stock ...
8h
Investor's Business Daily on MSNStock Market Today: Dow Jones Gains 650 Points; This Biotech Name Pops 12% And Tops 3 IBD Lists (Live Coverage)The Dow Jones and S&P 500 posted robust gains Friday afternoon. Nvidia led the Dow and Ulta topped the S&P 500 on the stock ...
Nasdaq plans to roll out 24-hour trading for U.S. companies in a move designed to modernize the market. | Nasdaq plans to ...
3 Beaten-Down Biotech Stocks to Buy Before They Soar. Wall Street Is Predicting Jumps of 68% to 250%.
14d
24/7 Wall St. on MSNThe Billionaire Baker Brothers Just Made This Big Biotech Stock MoveIf you’re interested in biotechnology stocks, billionaires Julian and Felix Baker are the ones to turn to. According to Forbes, the brothers, each worth an estimated $2.8 billion, run Baker Bros.
Insider trading activity involves company insiders, such as executives, directors, and employees, engaging in transactions of their own company's stock. Insiders' buy and sell transactions provide ...
09:45 EST Burning Rock Biotech (BNR) Ltd (ADR) trading halted, volatility trading pause Leverage the power of TipRanks' Smart Score, a data-driven tool to help you uncover top performing stocks ...
15:07 EST Maia Biotechnology (MAIA) Inc trading halted, news pending See what stocks are receiving strong buy ratings from top-rated analysts. Filter, analyze, and streamline your search for ...
The stock makes the NASDAQ top percentage gainers list on acquisition news today, currently trading at $8.44, up 3.48, ...
On Thursday, Moleculin Biotech, Inc., (NASDAQ:MBRX) stock is surging with a strong session volume of 64.85 million compared to an average volume of 157.048K, as per data from Benzinga Pro.
Moleculin Biotech stock surged on high volume after FDA guidance allowed a 10% reduction in its Phase 3 trial for Annamycin. The MIRACLE Phase 3 study's first unblinding at 45 subjects is expected ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results